Hiddo Heerspink, MD, PhD, highlights ASSIST trial data showing atrasentan reduced proteinuria by 25% on top of SGLT2 inhibitors in IgA nephropathy.
Hiddo Heerspink, PharmD, PhD
Advertisement
Hiddo Heerspink, PharmD, PhD, is a professor of Clinical Trials and Personalized Medicine, clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen.
Articles by Hiddo Heerspink, PharmD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
The HCPFive: Top News for Healthcare Providers from the Week of 06/21
2
Expanding Use of Dupilumab in Pediatric Patients, With Ilona Frieden, MD
3
When the Allergen Is Not What You Expected: 2 Contact Dermatitis Cases
4
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
5